Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

INTRODUCTION: The negative efficacy study examining the γ-secretase inhibitor semagacestat in mild to moderate Alzheimer’s disease (AD) included a number of biomarkers of the disease as well as safety outcomes. We analyzed these data to explore relationships between drug exposure and pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Doody, Rachelle S, Raman, Rema, Sperling, Reisa A, Seimers, Eric, Sethuraman, Gopalan, Mohs, Richard, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Sun, Xiaoying, Ernstrom, Karin, Thomas, Ronald G, Aisen, Paul S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461930/
https://www.ncbi.nlm.nih.gov/pubmed/26064192
http://dx.doi.org/10.1186/s13195-015-0121-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461930/
https://www.ncbi.nlm.nih.gov/pubmed/26064192
http://dx.doi.org/10.1186/s13195-015-0121-6

Ejemplares similares